Showing results (281-290 of 298) with videos related to
Sort By:
Pageof 30
JAMA Surgery|October 8, 2025
Minimally Invasive vs Open Left Pancreatectomy for Resectable Pancreatic Cancer: Long-Term Results of the Randomized DIPLOMA TrialCaro L Bruna, Jony van Hilst, Maarten Korrel, et al.Trials|April 9, 2017
Minimally invasive versus open distal pancreatectomy (LEOPARD): study protocol for a randomized controlled trialThijs de Rooij, Jony van Hilst, Jantien A Vogel, et al.Journal of the National Cancer Institute|September 3, 2025
Time-varying impact of established prognostic factors in resected pancreatic ductal adenocarcinomaAmmar A Javed, Asad Saulat Fatimi, Ingmar F Rompen, et al.HPB : the Official Journal of the International Hepato Pancreato Biliary Association|June 26, 2019
Implementation and outcome of minor and major minimally invasive liver surgery in the NetherlandsMarcel J van der Poel, Robert S Fichtinger, Marc Bemelmans, et al.Annals of Surgery|December 15, 2017
Alternative Fistula Risk Score for Pancreatoduodenectomy (a-FRS): Design and International External ValidationTimothy H Mungroop, L Bengt van Rijssen, David van Klaveren, et al.European Journal of Cancer (Oxford, England : 1990)|June 26, 2024
Prognostic value of total tumor volume in patients with colorectal liver metastases: A secondary analysis of the randomized CAIRO5 trial with external cohort validationJ Michiel Zeeuw, Nina J Wesdorp, Mahsoem Ali, et al.European Journal of Cancer (Oxford, England : 1990)|September 5, 2025
Total tumor volume predicts overall survival and response to induction chemotherapy in patients with colorectal cancer liver metastases: An ancillary study of the phase 3 CAIRO5 trialJ Michiel Zeeuw, Ruby Kemna, Mahsoem Ali, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2026
Thromboembolic Events During Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Cancer in the PREOPANC-2 TrialRuth A L Willems, Aniek E van Diepen, Esther N Dekker, et al.British Journal of Cancer|May 6, 2025
Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an international multicentre studyThomas F Stoop, Y H Andrew Wu, Atsushi Oba, et al.Lancet (London, England)|May 1, 2022
Algorithm-based care versus usual care for the early recognition and management of complications after pancreatic resection in the Netherlands: an open-label, nationwide, stepped-wedge cluster-randomised trialF Jasmijn Smits, Anne Claire Henry, Marc G Besselink, et al.Pageof 30